General Information of Drug (ID: DMOCQ9I)

Drug Name
N~3~-BENZYLPYRIDINE-2,3-DIAMINE Drug Info
Synonyms
N3-benzylpyridine-2,3-diamine; 79707-12-3; N~3~-Benzylpyridine-2,3-Diamine; N3-BENZYL-PYRIDINE-2,3-DIAMINE; 2-amino-3-benzylaminopyridine; 3-N-benzylpyridine-2,3-diamine; N~3~-Benzyl-2,3-pyridinediamine; aminopyridine 3; N'-benzylpyridine-2,3-diamine; 2ohm; 2,3-Pyridinediamine, N3-(phenylmethyl)-; CHEMBL435747; SCHEMBL11069733; CTK5E7044; BDBM15781; DTXSID40439234; 3-Substituted 2-Aminopyridine 5; MUKAGFLFIMVSQN-UHFFFAOYSA-N; MolPort-008-154-365; ALBB-013372; ZINC10339550; 9869AE; AKOS005174206; MCULE-5416742943; DB07281
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10397869
CAS Number
CAS 79707-12-3
TTD Drug ID
DMOCQ9I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Beta-secretase (BACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [2]
E-2609 DMTNUJ8 Alzheimer disease 8A20 Phase 3 [3]
verubecestat DM4CGH5 Alzheimer disease 8A20 Phase 3 [4]
Lanabecestat DMFJLB6 Alzheimer disease 8A20 Phase 3 [5]
AZD3293 DMJQHXD Alzheimer disease 8A20 Phase 2/3 [6]
JNJ-54861911 DMGPJ5U Alzheimer disease 8A20 Phase 2/3 [5]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [2]
LY2886721 DMV14LM Alzheimer disease 8A20 Phase 2 [7]
LY3202626 DM7IFNB Alzheimer disease 8A20 Phase 2 [5]
AZD-3839 DM72FOD Alzheimer disease 8A20 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [1]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
3 Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
4 BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
7 Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
8 Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.